Events

These events and webinars are intended for veterinary professionals only.

Event
Date and location

Zennovation in Sedation: Rethinking What is Possible #22551

Speaker:
Bridget Fitzpatrick, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

Tuesday, September 27, 2022, 19:00 - 20:00
location_on Dinner Meeting, Worcester, MA

Register now

View website

Verdinexor: A Novel Oral Therapy for Canine Lymphoma #22581

Speaker:
Jim Lowe, DVM

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM

1 RACE-Approved Credit  

RACE# 27059-900255 

Zennovation in Sedation: Rethinking What is Possible #22552

Speaker:
Bridget Fitzpatrick, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

Wednesday, September 28, 2022, 19:00 - 20:00
location_on Dinner Meeting, South Natick, MA

Register now

View website

Verdinexor: A Novel Oral Therapy for Canine Lymphoma #22609

Speaker:
Jim Lowe, DVM

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-900255 

Wednesday, September 28, 2022, 19:00 - 20:00
location_on Dinner Meeting, Greenwood, IN

Register now

View website

Zennovation in Sedation: Rethinking What is Possible #22601

Speaker:
Mike LaRosh, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

6:30 PM CDT

1 RACE-Approved Credit  

RACE# 27059-918761

The Impact of Feline Weight Loss #22151

Speaker:
Jim Lowe, DVM

Unintentional feline weight loss is a common, vague clinical sign, with serious health repercussions if not identified & addressed proactively.  This presentation  will review the significance of weight loss, metabolic factors that put cats at higher risk, and a multimodal approach to management. The presentation will also explore pharmacologic intervention, including FDA approved medication. 

10:00 PM Eastern, 7:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-890381 

Tuesday, October 4, 2022, 22:00 - 23:00
location_on Virtual Meeting

Register now

Zennovation in Sedation: Rethinking What is Possible #22592

Speaker:
Mike LaRosh, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

6:30 PM CDT

1 RACE-Approved Credit  

RACE# 27059-918761

Wednesday, October 5, 2022, 18:30 - 19:30
location_on Dinner Meeting, Rogers, AR

Register now

View website

Zennovation in Sedation: Rethinking What is Possible #22605

Speaker:
Jennifer Kasten, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

6:30 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

Wednesday, October 5, 2022, 19:00 - 20:00
location_on Dinner Meeting, Toledo, OH

Register now

View website

Verdinexor: A Novel Oral Therapy for Canine Lymphoma #221541

Speaker:
Elizabeth Mongol-Gunter, VMD

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-900255 

Wednesday, October 5, 2022, 19:00 - 20:00
location_on Dinner Meeting, Newark, DE

Register now

View website

Verdinexor: A Novel Oral Therapy for Canine Lymphoma #22152

Speaker:
Mike LaRosh, DVM

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

2:00 PM Eastern, 11:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-900255 

Thursday, October 6, 2022, 14:00 - 15:00
location_on Virtual Meeting

Register now

Zennovation in Sedation: Rethinking What is Possible #22606

Speaker:
Elizabeth Mongol-Gunter, VMD

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

Zennovation in Sedation: Rethinking What is Possible #22645

Speaker:
Steve Graff, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM MDT

1 RACE-Approved Credit  

RACE# 27059-918761

Tuesday, October 11, 2022, 19:00 - 20:00
location_on Dinner Meeting, Denver, CO

Register now

View website

Verdinexor: A Novel Oral Therapy for Canine Lymphoma #22631

Speaker:
Julie Kluxdal, DVM

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM PDT

1 RACE-Approved Credit  

RACE# 27059-900255 

Wednesday, October 12, 2022, 19:00 - 20:00
location_on Dinner Meeting, Glendale, CA

Register now

View website

Diagnosis and Management of Feline Hyperthyroidism #22153

Speaker:
Steve Graff, DVM

Feline hyperthyroidism is the most common endocrine disease affecting older cats. Prevalence has been reported as 10% in cats older than 10 years of age and is expected to rise. Left untreated, the disease can cause some potentially life-threatening metabolic disturbances. This presentation will review pathophysiology, diagnosis and treatment options in cats with feline hyperthyroidism. In addition, there are sections discussing co-management with chronic kidney disease and co-management with cardiovascular disease. 

7:00 PM Eastern, 4:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-893812 

Wednesday, October 12, 2022, 19:00 - 20:00
location_on Virtual Meeting

Register now

Zennovation in Sedation: Rethinking What is Possible #22154

Speaker:
Pam Mitchell, MS, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

12:00 PM Eastern, 9:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-918761

Tuesday, October 18, 2022, 12:00 - 13:00
location_on Virtual Meeting

Register now

Zennovation in Sedation: Rethinking What is Possible #22654

Speaker:
Jim Lowe, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM CDT

1 RACE-Approved Credit  

RACE# 27059-918761

Zennovation in Sedation: Rethinking What is Possible #22652

Speaker:
Mike LaRosh, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM CDT

1 RACE-Approved Credit  

RACE# 27059-918761

Tuesday, October 18, 2022, 19:00 - 20:00
location_on Dinner Meeting, Austin, TX

Register now

View website

Zennovation in Sedation: Rethinking What is Possible #22624

Speaker:
Bridget Fitzpatrick, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

6:30 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

Wednesday, October 19, 2022, 18:30 - 19:30
location_on Dinner Meeting, Concord, NH

Register now

View website

Zennovation in Sedation: Rethinking What is Possible #22637

Speaker:
Kathy Engler, DVM, DABVP

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM CDT

1 RACE-Approved Credit  

RACE# 27059-918761

Verdinexor: A Novel Oral Therapy for Canine Lymphoma #22653

Speaker:
Mike LaRosh, DVM

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM CDT

1 RACE-Approved Credit  

RACE# 27059-900255 

Wednesday, October 19, 2022, 19:00 - 20:00
location_on Dinner Meeting, Austin, TX

Register now

View website

Zennovation in Sedation: Rethinking What is Possible #22616

Speaker:
Kathy Engler, DVM, DABVP

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 CDT

1 RACE-Approved Credit  

RACE# 27059-918761

Zennovation in Sedation: Rethinking What is Possible #22636

Speaker:
Bridget Fitzpatrick, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

Thursday, October 20, 2022, 19:00 - 20:00
location_on Dinner Meeting, Derry, NH

Register now

View website

Canine Otitis Externa: Diagnosis, Management, and Success #22155

Speaker:
Elizabeth Mongol-Gunter, VMD

Canine otitis externa is one of the most frequently encountered conditions in small animal veterinary practice. This presentation explores the causes of canine otitis externa including the predisposing, primary and perpetuating factors, the importance of otic cytology, and the essential treatment modalities to help ensure clinical resolution. The development of a long-term maintenance cleaning and allergy management plan will also be discussed.

10:00 PM Eastern, 07:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-805774

Thursday, October 20, 2022, 22:00 - 23:00
location_on Virtual Meeting

Register now

Verdinexor: A Novel Oral Therapy for Canine Lymphoma #221541

Speaker:
Jim Lowe, DVM

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 P.M. CDT

1 RACE-Approved Credit  

RACE# 27059-900255 

Zennovation in Sedation: Rethinking What is Possible #22633

Speaker:
Elizabeth Mongol-Gunter, VMD

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

Wednesday, November 2, 2022, 19:00 - 20:00
location_on Dinner Meeting, Derry, NH

Register now

View website

Managing and Treating Canine Hypoadrenocorticism (Addison's Disease) #22157

Speaker:
Jennifer Kasten, DVM

This presentation provides a review of Canine Hypoadrenocorticism (Addison’s Disease); the topics include pathophysiology, signalment, clinical signs, diagnostics, treatment, and monitoring.  Cases will be discussed to reinforce your diagnostic confidence. 

7:00 PM Eastern, 4:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-894090 

Wednesday, November 2, 2022, 19:00 - 20:00
location_on Virtual Meeting

Register now

Navicular Syndrome and Clinical Application of Bisphosphonates in Equine Practice #22158

Speaker:
Brett Robinson, DVM

This presentation breaks down the complex mechanisms of bisphosphonates as a drug class and their use in managing the clinical signs of navicular syndrome in horses. The second half of the presentation explores the clinical features of non-nitrogenous bisphosphonates including their efficacy and safety in real world field applications. 

12:00 PM Eastern, 9:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-763173 

Thursday, November 10, 2022, 12:00 - 13:00
location_on Virtual Meeting

Register now

Zennovation in Sedation: Rethinking What is Possible #22159

Speaker:
Kathy Engler, DVM, DABVP

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

10:00 PM Eastern, 7:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-918761

Tuesday, November 15, 2022, 22:00 - 23:00
location_on Virtual Meeting

Register now

It's About Perfusion #22161

Speaker:
Elizabeth Mongol-Gunter, VMD

This presentation will review the components of an appropriate fluid plan including why fluids are useful, which fluid, and how to calculate the correct volume and rate.  In addition, monitoring guidelines to ensure the fluid plan is adequate and appropriate will be discussed.  Participants will also learn about the endothelial glycocalyx and its important role in maintaining normal vascular function. 

7:00 PM Eastern, 4:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-743915 

Tuesday, November 22, 2022, 19:00 - 20:00
location_on Virtual Meeting

Register now

Verdinexor: A Novel Oral Therapy for Canine Lymphoma #22162

Speaker:
Mike LaRosh, DVM

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

12:00 PM Eastern, 9:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-900255 

Wednesday, November 30, 2022, 12:00 - 13:00
location_on Virtual Meeting

Register now

"Zennovation in Sedation:Rethinking What is Possible" and "Verdinexor:A Novel Oral Therapy for Canine Lymphoma" #22648

Speaker:
Sam Gindville, DVM

Part 1: In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

Part 2: This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events.

7:00 PM EST

2 RACE-Approved Credit  

Wednesday, November 30, 2022, 19:00 - 20:00
location_on Dinner Meeting, Stuart, FL

Register now

View website

Update on Managing Canine Hyperadrenocorticism #22163

Speaker:
Timothy Smaha, DVM

Canine Hyperadrenocorticism (Cushing’s Disease) can be a challenging yet rewarding disease to manage. This presentation will review all aspects of Cushing’s: basic pathophysiology, clinical signs, diagnostics, differentiating tests, treatment and monitoring. A series of cases to increase  understanding of managing Cushing’s patients will be presented and the final  section highlights ways to  enhance owner compliance. 

10:00 PM Eastern, 7:00 PM Pacific 

1.5 RACE-Approved Credits  

RACE# 27059-869593 

Thursday, December 1, 2022, 22:00 - 23:00
location_on Virtual Meeting

Register now

Zennovation in Sedation: Rethinking What is Possible #22164

Speaker:
Jennifer Kasten, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

2:00 PM Eastern, 11:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-918761

Tuesday, December 6, 2022, 14:00 - 15:00
location_on Virtual Meeting

Register now

Verdinexor: A Novel Oral Therapy for Canine Lymphoma #22165

Speaker:
Elizabeth Mongol-Gunter, VMD

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM Eastern, 4:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-900255 

Thursday, December 8, 2022, 19:00 - 20:00
location_on Virtual Meeting

Register now

The Impact of Feline Weight Loss #22166

Speaker:
Bridget Fitzpatrick, DVM

Unintentional feline weight loss is a common, vague clinical sign, with serious health repercussions if not identified & addressed proactively.  This presentation  will review the significance of weight loss, metabolic factors that put cats at higher risk, and a multimodal approach to management. The presentation will also explore pharmacologic intervention, including FDA approved medication. 

12:00 PM Eastern, 9:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-890381 

Wednesday, December 14, 2022, 12:00 - 13:00
location_on Virtual Meeting

Register now

Zennovation in Sedation: Rethinking What is Possible #22167

Speaker:
Mike LaRosh, DVM

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

10:00 PM Eastern, 7:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-918761

Tuesday, December 20, 2022, 22:00 - 23:00
location_on Virtual Meeting

Register now

keyboard_arrow_up